Biomarkers in the field of obesity and its related comorbidities

Bibliography

• Flegal KM, Ogden CL, Yanovski JA, et al. High adiposity and high body mass index-for-age in us children and adolescents overall and by race-ethnic group. Am J Clin Nutr 2010;91(4):1020-102
   PubMed Web of Science ®Google Scholar
• Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009;53(21):1925-32
   PubMed Web of Science ®Google Scholar
• Freedman DS, Dietz WH, Srinivasan SR, et al. The relation of overweight to cardiovascular risk factors among children and adolescents: the bogalusa heart study. Pediatrics 1999;103(6 Pt 1):1175-82
   PubMed Web of Science ®Google Scholar
• Korner A, Kratzsch J, Gausche R, et al. New predictors of the metabolic syndrome in children – role of adipocytokines. Pediatr Res 2007;61(6):640-5
   PubMed Web of Science ®Google Scholar
• Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444(7121):881-7
   PubMed Web of Science ®Google Scholar
• Bluher M. The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Curr Opin Lipidol 2010;21(1):38-43
   PubMed Web of Science ®Google Scholar
• Liu J, Fox CS, Hickson DA, et al. Impact of abdominal visceral and subcutaneous adipose tissue on cardiometabolic risk factors: the jackson heart study. J Clin Endocrinol Metab 2010;95(12):5419-26
   PubMed Web of Science ®Google Scholar
• MacDougald OA, Burant CF. The rapidly expanding family of adipokines. Cell Metab 2007;6(3):159-61
   PubMed Web of Science ®Google Scholar
• Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010;314(1):1-16
   PubMed Web of Science ®Google Scholar
• Apovian CM, Bigornia S, Mott M, et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 2008;28(9):1654-9
   PubMed Web of Science ®Google Scholar
• Lowe GD, Rumley A, McMahon AD, et al. Interleukin-6, fibrin d-dimer, and coagulation factors vii and xiia in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004;24(8):1529-34
   PubMedGoogle Scholar
• Roytblat L, Rachinsky M, Fisher A, et al. Raised interleukin-6 levels in obese patients. Obes Res 2000;8(9):673-5
   PubMedGoogle Scholar
• Futrakul N, Sridama V, Futrakul P. Microalbuminuria – a biomarker of renal microvascular disease. Ren Fail 2009;31(2):140-3
   PubMed Web of Science ®Google Scholar
• Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106(14):1777-82
   PubMed Web of Science ®Google Scholar
• Green ED, Maffei M, Braden VV, et al. The human obese (ob) gene: RNA expression pattern and mapping on the physical, cytogenetic, and genetic maps of chromosome 7. Genome Res 1995;5(1):5-12
   PubMed Web of Science ®Google Scholar
• Lago F, Dieguez C, Gomez-Reino J, et al. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007;18(3-4):313-25
   PubMed Web of Science ®Google Scholar
• Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006;189(1):47-60
   PubMed Web of Science ®Google Scholar
• Enriori PJ, Evans AE, Sinnayah P, et al. Leptin resistance and obesity. Obesity (Silver Spring) 2006;14(Suppl 5):254S-8S
   PubMedGoogle Scholar
• Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F, et al. Relation of increased leptin concentrations to history of myocardial infarction and stroke in the united states population. Am J Cardiol 2007;100(2):234-9
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Lowe GD, Rumley A, et al. Adipokines and risk of type 2 diabetes in older men. Diabetes Care 2007;30(5):1200-5
   PubMed Web of Science ®Google Scholar
• Bouloumie A, Marumo T, Lafontan M, et al. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999;13(10):1231-8
   PubMed Web of Science ®Google Scholar
• Dedoussis GV, Kapiri A, Samara A, et al. Visfatin: the link between inflammation and childhood obesity. Diabetes Care 2009;32(6):e71
   PubMedGoogle Scholar
• Nordfors L, Lonnqvist F, Heimburger O, et al. Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 1998;54(4):1267-75
   PubMedGoogle Scholar
• Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens 2006;24(5):789-801
   PubMed Web of Science ®Google Scholar
• Patel SD, Rajala MW, Rossetti L, et al. Disulfide-dependent multimeric assembly of resistin family hormones. Science 2004;304(5674):1154-8
   PubMed Web of Science ®Google Scholar
• Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409(6818):307-12
   PubMed Web of Science ®Google Scholar
• Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. Trends Endocrinol Metab 2011;22(7):259-65
   PubMed Web of Science ®Google Scholar
• Adeghate E. An update on the biology and physiology of resistin. Cell Mol Life Sci 2004;61(19-20):2485-96
   PubMedGoogle Scholar
• Gui Y, Silha JV, Mishra S, et al. Changes in adipokine expression during food deprivation in the mouse and the relationship to fasting-induced insulin resistance. Can J Physiol Pharmacol 2003;81(10):979-85
   PubMedGoogle Scholar
• Rajala MW, Qi Y, Patel HR, et al. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 2004;53(7):1671-9
   PubMed Web of Science ®Google Scholar
• Sato N, Kobayashi K, Inoguchi T, et al. Adenovirus-mediated high expression of resistin causes dyslipidemia in mice. Endocrinology 2005;146(1):273-9
   PubMed Web of Science ®Google Scholar
• Kusminski CM, McTernan PG, Kumar S. Role of resistin in obesity, insulin resistance and type ii diabetes. Clin Sci (Lond) 2005;109(3):243-56
   PubMed Web of Science ®Google Scholar
• Graveleau C, Zaha VG, Mohajer A, et al. Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action. J Biol Chem 2005;280(36):31679-85
   PubMedGoogle Scholar
• Kunnari A, Ukkola O, Paivansalo M, et al. High plasma resistin level is associated with enhanced highly sensitive c-reactive protein and leukocytes. J Clin Endocrinol Metab 2006;91(7):2755-60
   PubMed Web of Science ®Google Scholar
• Lubos E, Messow CM, Schnabel R, et al. Resistin, acute coronary syndrome and prognosis results from the atherogene study. Atherosclerosis 2007;193(1):121-8
   PubMed Web of Science ®Google Scholar
• Norata GD, Ongari M, Garlaschelli K, et al. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007;156(2):279-84
   PubMedGoogle Scholar
• Milan G, Granzotto M, Scarda A, et al. Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss. Obes Res 2002;10(11):1095-103
   PubMedGoogle Scholar
• Silswal N, Singh AK, Aruna B, et al. Human resistin stimulates the pro-inflammatory cytokines tnf-alpha and il-12 in macrophages by nf-kappab-dependent pathway. Biochem Biophys Res Commun 2005;334(4):1092-101
   PubMed Web of Science ®Google Scholar
• Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96(5):1723-32
   PubMed Web of Science ®Google Scholar
• Wulster-Radcliffe MC, Ajuwon KM, Wang J, et al. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004;316(3):924-9
   PubMed Web of Science ®Google Scholar
• Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of crp, tnf-alpha and il-6. Diabetes Res Clin Pract 2005;69(1):29-35
   PubMed Web of Science ®Google Scholar
• Andersson CX, Gustafson B, Hammarstedt A, et al. Inflamed adipose tissue, insulin resistance and vascular injury. Diabetes Metab Res Rev 2008;24(8):595-603
   PubMedGoogle Scholar
• Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab 2005;19(4):547-66
   PubMedGoogle Scholar
• Bluher M, Fasshauer M, Tonjes A, et al. Association of interleukin-6, c-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes 2005;113(9):534-7
   PubMed Web of Science ®Google Scholar
• Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83(3):847-50
   PubMed Web of Science ®Google Scholar
• Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85(9):3338-42
   PubMed Web of Science ®Google Scholar
• Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002;105(7):804-9
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286(3):327-34
   PubMed Web of Science ®Google Scholar
• Feve B, Bastard JP. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5(6):305-11
   PubMed Web of Science ®Google Scholar
• Rotter V, Nagaev I, Smith U. Interleukin-6 (il-6) induces insulin resistance in 3t3-l1 adipocytes and is, like il-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003;278(46):45777-84
   PubMed Web of Science ®Google Scholar
• Mariani E, Neri S, Cattini L, et al. Effect of zinc supplementation on plasma il-6 and mcp-1 production and nk cell function in healthy elderly: interactive influence of +647 mt1a and -174 il-6 polymorphic alleles. Exp Gerontol 2008;43(5):462-71
   PubMedGoogle Scholar
• Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307(5708):426-30
   PubMed Web of Science ®Google Scholar
• Samal B, Sun Y, Stearns G, et al. Cloning and characterization of the cDNA encoding a novel human pre-b-cell colony-enhancing factor. Mol Cell Biol 1994;14(2):1431-7
   PubMed Web of Science ®Google Scholar
• Sethi JK, Vidal-Puig A. Visfatin. The missing link between intra-abdominal obesity and diabetes? Trends Mol Med 2005;11(8):344-7
   PubMed Web of Science ®Google Scholar
• Kloting N, Kloting I. Visfatin: gene expression in isolated adipocytes and sequence analysis in obese wokw rats compared with lean control rats. Biochem Biophys Res Commun 2005;332(4):1070-2
   PubMed Web of Science ®Google Scholar
• Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mrna expression in humans. Diabetes 2005;54(10):2911-16
   PubMed Web of Science ®Google Scholar
• Esteghamati A, Alamdari A, Zandieh A, et al. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Res Clin Pract 2011;91(2):154-8
   PubMedGoogle Scholar
• Zhu J, Schott M, Liu R, et al. Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes. Horm Metab Res 2008;40(11):801-5
   PubMedGoogle Scholar
• Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178(3):1748-58
   PubMed Web of Science ®Google Scholar
• Araki S, Dobashi K, Kubo K, et al. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity (Silver Spring) 2008;16(2):384-8
   PubMedGoogle Scholar
• Taskesen D, Kirel B, Us T. Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. J Clin Res Pediatr Endocrinol 2012;4(2):76-81
   PubMedGoogle Scholar
• Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, et al. Serum concentration of visfatin in obese women. Metabolism 2007;56(8):1131-4
   PubMed Web of Science ®Google Scholar
• Zhong M, Tan HW, Gong HP, et al. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008;69(6):878-84
   PubMed Web of Science ®Google Scholar
• Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005;102(30):10610-15
   PubMed Web of Science ®Google Scholar
• Ko BJ, Lee M, Park HS, et al. Elevated vaspin and leptin levels are associated with obesity in prepubertal korean children. Endocr J 2013;60(5):609-16
   PubMed Web of Science ®Google Scholar
• El-Mesallamy HO, Kassem DH, El-Demerdash E, et al. Vaspin and visfatin/nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 2011;60(1):63-70
   PubMedGoogle Scholar
• von Loeffelholz C, Mohlig M, Arafat AM, et al. Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans. Eur J Endocrinol 2010;162(3):507-13
   PubMedGoogle Scholar
• Youn BS, Kloting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008;57(2):372-7
   PubMed Web of Science ®Google Scholar
• Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93(11 Suppl 1):S64-73
   PubMed Web of Science ®Google Scholar
• Gonzalez CR, Caminos JE, Vazquez MJ, et al. Regulation of visceral adipose tissue-derived serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue. J Physiol 2009;587(Pt 14):3741-50
   PubMedGoogle Scholar
• Kang ES, Magkos F, Sienkiewicz E, et al. Circulating vaspin and visfatin are not affected by acute or chronic energy deficiency or leptin administration in humans. Eur J Endocrinol 2011;164(6):911-17
   PubMedGoogle Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259(5091):87-91
   PubMed Web of Science ®Google Scholar
• Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112(12):1796-808
   PubMed Web of Science ®Google Scholar
• Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95(5):2111-19
   PubMed Web of Science ®Google Scholar
• Hivert MF, Sullivan LM, Fox CS, et al. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab 2008;93(8):3165-72
   PubMed Web of Science ®Google Scholar
• Dominguez H, Storgaard H, Rask-Madsen C, et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005;42(6):517-25
   PubMed Web of Science ®Google Scholar
• Stanley TL, Zanni MV, Johnsen S, et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 2011;96(1):E146-50
   PubMed Web of Science ®Google Scholar
• Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003;198(7):977-85
   PubMed Web of Science ®Google Scholar
• Wittamer V, Bondue B, Guillabert A, et al. Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity. J Immunol 2005;175(1):487-93
   PubMedGoogle Scholar
• Zabel BA, Silverio AM, Butcher EC. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J Immunol 2005;174(1):244-51
   PubMed Web of Science ®Google Scholar
• Goralski KB, McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007;282(38):28175-88
   PubMed Web of Science ®Google Scholar
• Muruganandan S, Roman AA, Sinal CJ. Role of chemerin/cmklr1 signaling in adipogenesis and osteoblastogenesis of bone marrow stem cells. J Bone Miner Res 2010;25(2):222-34
   PubMedGoogle Scholar
• Muruganandan S, Parlee SD, Rourke JL, et al. Chemerin, a novel peroxisome proliferator-activated receptor gamma (ppargamma) target gene that promotes mesenchymal stem cell adipogenesis. J Biol Chem 2011;286(27):23982-95
   PubMed Web of Science ®Google Scholar
• Ernst MC, Haidl ID, Zuniga LA, et al. Disruption of the chemokine-like receptor-1 (cmklr1) gene is associated with reduced adiposity and glucose intolerance. Endocrinology 2012;153(2):672-82
   PubMed Web of Science ®Google Scholar
• Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab 2010;21(11):660-7
   PubMed Web of Science ®Google Scholar
• Catalan V, Gomez-Ambrosi J, Rodriguez A, et al. Increased levels of chemerin and its receptor, chemokine-like receptor-1, in obesity are related to inflammation: tumor necrosis factor-alpha stimulates mrna levels of chemerin in visceral adipocytes from obese patients. Surg Obes Relat Dis 2013;9(2):306-14
   PubMedGoogle Scholar
• Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007;148(10):4687-94
   PubMed Web of Science ®Google Scholar
• Bozaoglu K, Segal D, Shields KA, et al. Chemerin is associated with metabolic syndrome phenotypes in a mexican-american population. J Clin Endocrinol Metab 2009;94(8):3085-8
   PubMed Web of Science ®Google Scholar
• Dong B, Ji W, Zhang Y. Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome. Intern Med 2011;50(10):1093-7
   PubMed Web of Science ®Google Scholar
• Ouwens DM, Bekaert M, Lapauw B, et al. Chemerin as biomarker for insulin sensitivity in males without typical characteristics of metabolic syndrome. Arch Physiol Biochem 2012;118(3):135-8
   PubMed Web of Science ®Google Scholar
• Landgraf K, Friebe D, Ullrich T, et al. Chemerin as a mediator between obesity and vascular inflammation in children. J Clin Endocrinol Metab 2012;97(4):E556-64
   PubMed Web of Science ®Google Scholar
• Bermudez-Silva FJ, Cardinal P, Cota D. The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J Psychopharmacol 2012;26(1):114-24
   PubMedGoogle Scholar
• Quarta C, Mazza R, Obici S, et al. Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol Med 2011;17(9):518-26
   PubMedGoogle Scholar
• Kunos G, Tam J. The case for peripheral cb(1) receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol 2011;163(7):1423-31
   PubMed Web of Science ®Google Scholar
• Matias I, Bisogno T, Di Marzo V. Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. Int J Obes (Lond) 2006;30(Suppl 1):S7-S12
   PubMedGoogle Scholar
• Matias I, Gonthier MP, Petrosino S, et al. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br J Pharmacol 2007;152(5):676-90
   PubMedGoogle Scholar
• Cote M, Matias I, Lemieux I, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007;31(4):692-9
   PubMed Web of Science ®Google Scholar
• Sipe JC, Scott TM, Murray S, et al. Biomarkers of endocannabinoid system activation in severe obesity. PLoS One 2010;5(1):e8792
   PubMedGoogle Scholar
• Matias I, Gatta-Cherifi B, Tabarin A, et al. Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS One 2012;7(7):e42399
   PubMed Web of Science ®Google Scholar
• Modeer T, Blomberg CC, Wondimu B, et al. Association between obesity, flow rate of whole saliva, and dental caries in adolescents. Obesity (Silver Spring) 2010;18(12):2367-73
   PubMedGoogle Scholar
• Powers PS, Holland P, Miller C, et al. Salivation patterns of obese and normal subjects. Int J Obes 1982;6(3):267-70
   PubMedGoogle Scholar
• Auguet T, Quintero Y, Terra X, et al. Upregulation of lipocalin 2 in adipose tissues of severely obese women: positive relationship with proinflammatory cytokines. Obesity (Silver Spring) 2011;19(12):2295-300
   PubMedGoogle Scholar
• Akelma AZ, Abaci A, Ozdemir O, et al. The association of serum lipocalin-2 levels with metabolic and clinical parameters in obese children: a pilot study. J Pediatr Endocrinol Metab 2012;25(5-6):525-8
   PubMedGoogle Scholar
• Qu H, Deng H, Hu Z. Plasma progranulin concentrations are increased in patients with type 2 diabetes and obesity and correlated with insulin resistance. Mediators Inflamm 2013;2013:360190
   PubMedGoogle Scholar
• O'Dowd BF, Heiber M, Chan A, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993;136(1-2):355-60
   PubMed Web of Science ®Google Scholar
• Castan-Laurell I, Dray C, Attane C, et al. Apelin, diabetes, and obesity. Endocrine 2011;40(1):1-9
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26(3):439-51
   PubMed Web of Science ®Google Scholar
• Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436(7049):356-62
   PubMed Web of Science ®Google Scholar
• Flower DR. The lipocalin protein family: structure and function. Biochem J 1996;318(Pt 1):1-14
   PubMed Web of Science ®Google Scholar
• Newcomer ME, Ong DE. Plasma retinol binding protein: structure and function of the prototypic lipocalin. Biochim Biophys Acta 2000;1482(1-2):57-64
   PubMedGoogle Scholar
• Graham TE, Yang Q, Bluher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354(24):2552-63
   PubMed Web of Science ®Google Scholar
• Cho YM, Youn BS, Lee H, et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006;29(11):2457-61
   PubMed Web of Science ®Google Scholar
• Kloting N, Graham TE, Berndt J, et al. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab 2007;6(1):79-87
   PubMed Web of Science ®Google Scholar
• Haider DG, Schindler K, Prager G, et al. Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab 2007;92(3):1168-71
   PubMed Web of Science ®Google Scholar
• Broch M, Vendrell J, Ricart W, et al. Circulating retinol-binding protein-4, insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects. Diabetes Care 2007;30(7):1802-6
   PubMed Web of Science ®Google Scholar
• Aeberli I, Biebinger R, Lehmann R, et al. Serum retinol-binding protein 4 concentration and its ratio to serum retinol are associated with obesity and metabolic syndrome components in children. J Clin Endocrinol Metab 2007;92(11):4359-65
   PubMed Web of Science ®Google Scholar
• Ailhaud G, Grimaldi P, Negrel R. Cellular and molecular aspects of adipose tissue development. Annu Rev Nutr 1992;12:207-33
   PubMed Web of Science ®Google Scholar
• Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 2001;104(4):531-43
   PubMed Web of Science ®Google Scholar
• Crandall DL, Hausman GJ, Kral JG. A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. Microcirculation 1997;4(2):211-32
   PubMed Web of Science ®Google Scholar
• Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000;14(17):2123-33
   PubMed Web of Science ®Google Scholar
• Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516
   PubMed Web of Science ®Google Scholar
• Roberts CK, Won D, Pruthi S, et al. Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, mmp-9, and monocyte chemotactic activity in men with metabolic syndrome factors. J Appl Physiol 2006;100(5):1657-65
   PubMed Web of Science ®Google Scholar
• Tinahones FJ, Coin-Araguez L, Mayas MD, et al. Obesity-associated insulin resistance is correlated to adipose tissue vascular endothelial growth factors and metalloproteinase levels. BMC Physiol 2012;12:4
   PubMedGoogle Scholar
• Unal R, Yao-Borengasser A, Varma V, et al. Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone. J Clin Endocrinol Metab 2010;95(6):2993-3001
   PubMedGoogle Scholar
• Bouloumie A, Sengenes C, Portolan G, et al. Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes 2001;50(9):2080-6
   PubMed Web of Science ®Google Scholar
• Derosa G, Ferrari I, D'Angelo A, et al. Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 2008;15(4):219-24
   PubMed Web of Science ®Google Scholar
• Lee DK, George SR, O'Dowd BF. Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci 2006;27(4):190-4
   PubMed Web of Science ®Google Scholar
• Heinonen MV, Purhonen AK, Miettinen P, et al. Apelin, orexin-a and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept 2005;130(1-2):7-13
   PubMedGoogle Scholar
• Soriguer F, Garrido-Sanchez L, Garcia-Serrano S, et al. Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus. Obes Surg 2009;19(11):1574-80
   PubMed Web of Science ®Google Scholar
• Habata Y, Fujii R, Hosoya M, et al. Apelin, the natural ligand of the orphan receptor apj, is abundantly secreted in the colostrum. Biochim Biophys Acta 1999;1452(1):25-35
   PubMed Web of Science ®Google Scholar
• Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the apj receptor. J Neurochem 2000;74(1):34-41
   PubMed Web of Science ®Google Scholar
• Katugampola SD, Maguire JJ, Matthewson SR, et al. [(125)i]-(pyr(1))apelin-13 is a novel radioligand for localizing the apj orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 2001;132(6):1255-60
   PubMed Web of Science ®Google Scholar
• Taheri S, Murphy K, Cohen M, et al. The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochem Biophys Res Commun 2002;291(5):1208-12
   PubMed Web of Science ®Google Scholar
• Li L, Yang G, Li Q, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006;114(10):544-8
   PubMed Web of Science ®Google Scholar
• Castan-Laurell I, Vitkova M, Daviaud D, et al. Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and apj. Eur J Endocrinol 2008;158(6):905-10
   PubMed Web of Science ®Google Scholar
• Erdem G, Dogru T, Tasci I, et al. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008;116(5):289-92
   PubMedGoogle Scholar
• Zhang Y, Shen C, Li X, et al. Low plasma apelin in newly diagnosed type 2 diabetes in chinese people. Diabetes Care 2009;32(12):e150
   PubMedGoogle Scholar
• Higuchi K, Masaki T, Gotoh K, et al. Apelin, an apj receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology 2007;148(6):2690-7
   PubMedGoogle Scholar
• Malyszko J, Malyszko JS, Pawlak K, et al. Apelin, a novel adipocytokine, in relation to endothelial function and inflammation in kidney allograft recipients. Transplant Proc 2008;40(10):3466-9
   PubMed Web of Science ®Google Scholar
• Heinonen MV, Laaksonen DE, Karhu T, et al. Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis 2009;19(9):626-33
   PubMed Web of Science ®Google Scholar
• Yu S, Zhang Y, Li MZ, et al. Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients. Chin Med J 2012;125(19):3440-4
   PubMedGoogle Scholar
• Daviaud D, Boucher J, Gesta S, et al. TNF-alpha up-regulates apelin expression in human and mouse adipose tissue. FASEB J 2006;20(9):1528-30
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kihara S, Funahashi T, et al. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003;14(6):561-6
   PubMed Web of Science ®Google Scholar
• Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257(1):79-83
   PubMed Web of Science ®Google Scholar
• Wang Y, Lam KS, Yau MH, et al. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 2008;409(3):623-33
   PubMedGoogle Scholar
• Schober F, Neumeier M, Weigert J, et al. Low molecular weight adiponectin negatively correlates with the waist circumference and monocytic il-6 release. Biochem Biophys Res Commun 2007;361(4):968-73
   PubMedGoogle Scholar
• Pajvani UB, Du X, Combs TP, et al. Structure-function studies of the adipocyte-secreted hormone acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 2003;278(11):9073-85
   PubMed Web of Science ®Google Scholar
• Fisher FM, Trujillo ME, Hanif W, et al. Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in indo-asian males. Diabetologia 2005;48(6):1084-7
   PubMedGoogle Scholar
• Hall JE, Kuo JJ, da Silva AA, et al. Obesity-associated hypertension and kidney disease. Curr Opin Nephrol Hypertens 2003;12(2):195-200
   PubMedGoogle Scholar
• Tsioufis C, Dimitriadis K, Selima M, et al. Low-grade inflammation and hypoadiponectinaemia have an additive detrimental effect on aortic stiffness in essential hypertensive patients. Eur Heart J 2007;28(9):1162-9
   PubMedGoogle Scholar
• Chow WS, Cheung BM, Tso AW, et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007;49(6):1455-61
   PubMed Web of Science ®Google Scholar
• Schaffler A, Neumeier M, Herfarth H, et al. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 2005;1732(1-3):96-102
   PubMed Web of Science ®Google Scholar
• Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006;290(6):E1253-61
   PubMed Web of Science ®Google Scholar
• de Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007;56(6):1655-61
   PubMed Web of Science ®Google Scholar
• Auguet T, Quintero Y, Riesco D, et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet 2011;12:60
   PubMed Web of Science ®Google Scholar
• Moreno-Navarrete JM, Catalan V, Ortega F, et al. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 2010;7:27
   PubMed Web of Science ®Google Scholar
• Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010;88(1):29-33
   PubMed Web of Science ®Google Scholar
• Moreno-Navarrete JM, Ortega F, Castro A, et al. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring) 2011;19(8):1552-9
   PubMedGoogle Scholar
• Prats-Puig A, Bassols J, Bargallo E, et al. Toward an early marker of metabolic dysfunction: omentin-1 in prepubertal children. Obesity (Silver Spring) 2011;19(9):1905-7
   PubMed Web of Science ®Google Scholar
• Fain JN, Sacks HS, Buehrer B, et al. Identification of omentin mrna in human epicardial adipose tissue: comparison to omentin in subcutaneous, internal mammary artery periadventitial and visceral abdominal depots. Int J Obes (Lond) 2008;32(5):810-15
   PubMed Web of Science ®Google Scholar
• Maruyama S, Shibata R, Kikuchi R, et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J Biol Chem 2012;287(1):408-17
   PubMedGoogle Scholar
• Yamawaki H, Kuramoto J, Kameshima S, et al. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011;408(2):339-43
   PubMed Web of Science ®Google Scholar
• Shibata R, Ouchi N, Kikuchi R, et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis 2011;219(2):811-14
   PubMed Web of Science ®Google Scholar
• Oh IS, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006;443(7112):709-12
   PubMed Web of Science ®Google Scholar
• Ramanjaneya M, Chen J, Brown JE, et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 2010;151(7):3169-80
   PubMed Web of Science ®Google Scholar
• Tsuchiya T, Shimizu H, Yamada M, et al. Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in non-obese males. Clin Endocrinol (Oxf) 2010;73(4):484-90
   PubMedGoogle Scholar
• Tan BK, Hallschmid M, Kern W, et al. Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/nucb-2, in obese humans: evidence of nesfatin-1/nucb-2 resistance and implications for obesity treatment. J Clin Endocrinol Metab 2011;96(4):E669-73
   PubMed Web of Science ®Google Scholar
• Chaolu H, Asakawa A, Ushikai M, et al. Effect of exercise and high-fat diet on plasma adiponectin and nesfatin levels in mice. Exp Ther Med 2011;2(2):369-73
   PubMedGoogle Scholar
• Yamawaki H, Takahashi M, Mukohda M, et al. A novel adipocytokine, nesfatin-1 modulates peripheral arterial contractility and blood pressure in rats. Biochem Biophys Res Commun 2012;418(4):676-81
   PubMedGoogle Scholar
• Yosten GL, Redlinger L, Samson WK. Evidence for a role of endogenous nesfatin-1 in the control of water drinking. J Neuroendocrinol 2012;24(7):1078-84
   PubMedGoogle Scholar
• Gotoh K, Masaki T, Chiba S, et al. Nesfatin-1, corticotropin-releasing hormone, thyrotropin-releasing hormone, and neuronal histamine interact in the hypothalamus to regulate feeding behavior. J Neurochem 2013;124(1):90-9
   PubMed Web of Science ®Google Scholar
• Gunay H, Tutuncu R, Aydin S, et al. Decreased plasma nesfatin-1 levels in patients with generalized anxiety disorder. Psychoneuroendocrinology 2012;37(12):1949-53
   PubMed Web of Science ®Google Scholar
• Yang M, Zhang Z, Wang C, et al. Nesfatin-1 action in the brain increases insulin sensitivity through akt/ampk/torc2 pathway in diet-induced insulin resistance. Diabetes 2012;61(8):1959-68
   PubMedGoogle Scholar
• Thacher TD, Clarke BL. Vitamin D insufficiency. Mayo Clin Proc 2011;86(1):50-60
   PubMed Web of Science ®Google Scholar
• Earthman CP, Beckman LM, Masodkar K, et al. The link between obesity and low circulating 25-hydroxyvitamin d concentrations: considerations and implications. Int J Obes (Lond) 2012;36(3):387-96
   PubMed Web of Science ®Google Scholar
• Alemzadeh R, Kichler J, Babar G, et al. Hypovitaminosis d in obese children and adolescents: relationship with adiposity, insulin sensitivity, ethnicity, and season. Metabolism 2008;57(2):183-91
   PubMed Web of Science ®Google Scholar
• Guillot X, Semerano L, Saidenberg-Kermanac'h N, et al. Vitamin D and inflammation. Joint Bone Spine 2010;77(6):552-7
   PubMed Web of Science ®Google Scholar
• Codoner-Franch P, Tavarez-Alonso S, Simo-Jorda R, et al. Vitamin D status is linked to biomarkers of oxidative stress, inflammation, and endothelial activation in obese children. J Pediatr 2012;161(5):848-54
   PubMed Web of Science ®Google Scholar
• Namen AE, Schmierer AE, March CJ, et al. B cell precursor growth-promoting activity. Purification and characterization of a growth factor active on lymphocyte precursors. J Exp Med 1988;167(3):988-1002
   PubMedGoogle Scholar
• Khaled AR, Durum SK. Lymphocide: cytokines and the control of lymphoid homeostasis. Nat Rev Immunol 2002;2(11):817-30
   PubMedGoogle Scholar
• von Freeden-Jeffry U, Vieira P, Lucian LA, et al. Lymphopenia in interleukin (il)-7 gene-deleted mice identifies il-7 as a nonredundant cytokine. J Exp Med 1995;181(4):1519-26
   PubMed Web of Science ®Google Scholar
• Peschon JJ, Morrissey PJ, Grabstein KH, et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 1994;180(5):1955-60
   PubMed Web of Science ®Google Scholar
• Puel A, Ziegler SF, Buckley RH, et al. Defective il7r expression in t(-)b(+)nk(+) severe combined immunodeficiency. Nat Genet 1998;20(4):394-7
   PubMed Web of Science ®Google Scholar
• Puel A, Leonard WJ. Mutations in the gene for the il-7 receptor result in t(-)b(+)nk(+) severe combined immunodeficiency disease. Curr Opin Immunol 2000;12(4):468-73
   PubMedGoogle Scholar
• Maury E, Ehala-Aleksejev K, Guiot Y, et al. Adipokines oversecreted by omental adipose tissue in human obesity. Am J Physiol Endocrinol Metab 2007;293(3):E656-65
   PubMed Web of Science ®Google Scholar
• Alderson MR, Tough TW, Ziegler SF, et al. Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. J Exp Med 1991;173(4):923-30
   PubMedGoogle Scholar
• Kelly EA, Koziol-White CJ, Clay KJ, et al. Potential contribution of il-7 to allergen-induced eosinophilic airway inflammation in asthma. J Immunol 2009;182(3):1404-10
   PubMedGoogle Scholar
• Araujo DM, Cotman CW. Trophic effects of interleukin-4, -7 and -8 on hippocampal neuronal cultures: potential involvement of glial-derived factors. Brain Res 1993;600(1):49-55
   PubMedGoogle Scholar
• Macia L, Viltart O, Delacre M, et al. Interleukin-7, a new cytokine targeting the mouse hypothalamic arcuate nucleus: role in body weight and food intake regulation. PLoS One 2010;5(4):e9953
   PubMedGoogle Scholar
• Lucas S, Taront S, Magnan C, et al. Interleukin-7 regulates adipose tissue mass and insulin sensitivity in high-fat diet-fed mice through lymphocyte-dependent and independent mechanisms. PLoS One 2012;7(6):e40351
   PubMed Web of Science ®Google Scholar
• Jacobs SR, Michalek RD, Rathmell JC. Il-7 is essential for homeostatic control of t cell metabolism in vivo. J Immunol 2010;184(7):3461-9
   PubMedGoogle Scholar
• Juge-Aubry CE, Somm E, Pernin A, et al. Adipose tissue is a regulated source of interleukin-10. Cytokine 2005;29(6):270-4
   PubMed Web of Science ®Google Scholar
• Maiorino MI, Schisano B, Di Palo C, et al. Interleukin-20 circulating levels in obese women: effect of weight loss. Nutr Metab Cardiovasc Dis 2010;20(3):180-5
   PubMedGoogle Scholar
• Bassols J, Botas P, Moreno-Navarrete JM, et al. Environmental and genetic factors influence the relationship between circulating il-10 and obesity phenotypes. Obesity (Silver Spring) 2010;18(3):611-18
   PubMedGoogle Scholar
• Formoso G, Taraborrelli M, Guagnano MT, et al. Magnetic resonance imaging determined visceral fat reduction associates with enhanced il-10 plasma levels in calorie restricted obese subjects. PLoS One 2012;7(12):e52774
   PubMedGoogle Scholar
• Carson WE, Giri JG, Lindemann MJ, et al. Interleukin (il) 15 is a novel cytokine that activates human natural killer cells via components of the il-2 receptor. J Exp Med 1994;180(4):1395-403
   PubMed Web of Science ®Google Scholar
• Carson WE, Fehniger TA, Haldar S, et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 1997;99(5):937-43
   PubMed Web of Science ®Google Scholar
• Barra NG, Reid S, MacKenzie R, et al. Interleukin-15 contributes to the regulation of murine adipose tissue and human adipocytes. Obesity (Silver Spring) 2010;18(8):1601-7
   PubMed Web of Science ®Google Scholar
• Nielsen AR, Hojman P, Erikstrup C, et al. Association between interleukin-15 and obesity: interleukin-15 as a potential regulator of fat mass. J Clin Endocrinol Metab 2008;93(11):4486-93
   PubMed Web of Science ®Google Scholar
• Quinn LS, Anderson BG, Strait-Bodey L, et al. Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. Am J Physiol Endocrinol Metab 2009;296(1):E191-202
   PubMed Web of Science ®Google Scholar
• Carbo N, Lopez-Soriano J. Costelli, P et al. Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochim Biophys Acta 2001;1526(1):17-24
   PubMed Web of Science ®Google Scholar
• Lopez-Soriano J, Carbo N, Almendro V, et al. Rat liver lipogenesis is modulated by interleukin-15. Int J Mol Med 2004;13(6):817-19
   PubMedGoogle Scholar
• Barra NG, Chew MV, Reid S, et al. Interleukin-15 treatment induces weight loss independent of lymphocytes. PLoS One 2012;7(6):e39553
   PubMedGoogle Scholar
• Mandrup-Poulsen T, Zumsteg U, Reimers J, et al. Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic beta-cell destruction in insulin-dependent diabetes mellitus. Cytokine 1993;5(3):185-91
   PubMedGoogle Scholar
• Charles BA, Doumatey A, Huang H, et al. The roles of il-6, il-10, and il-1ra in obesity and insulin resistance in african-americans. J Clin Endocrinol Metab 2011;96(12):E2018-22
   PubMedGoogle Scholar
• Suhre K, Meisinger C, Doring A, et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One 2010;5(11):e13953
   PubMed Web of Science ®Google Scholar
• Mihalik SJ, Goodpaster BH, Kelley DE, et al. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring) 2010;18(9):1695-700
   PubMed Web of Science ®Google Scholar
• Pietilainen KH, Sysi-Aho M, Rissanen A, et al. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects – a monozygotic twin study. PLoS One 2007;2(2):e218
   PubMedGoogle Scholar
• Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009;9(4):311-26
   PubMed Web of Science ®Google Scholar
• Kim JY, Park JY, Kim OY, et al. Metabolic profiling of plasma in overweight/obese and lean men using ultra performance liquid chromatography and q-tof mass spectrometry (uplc-q-tof ms). J Proteome Res 2010;9(9):4368-75
   PubMedGoogle Scholar
• Mihalik SJ, Michaliszyn SF, de las Heras J, et al. Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and type 2 diabetes: evidence for enhanced mitochondrial oxidation. Diabetes Care 2012;35(3):605-11
   PubMed Web of Science ®Google Scholar
• Wahl S, Yu Z, Kleber M, et al. Childhood obesity is associated with changes in the serum metabolite profile. Obes Facts 2012;5(5):660-70
   PubMed Web of Science ®Google Scholar
• Houten SM, Wanders RJ. A general introduction to the biochemistry of mitochondrial fatty acid beta-oxidation. J Inherit Metab Dis 2010;33(5):469-77
   PubMed Web of Science ®Google Scholar
• Widhalm K, Zwiauer K, Hayde M, et al. Plasma concentrations of free amino acids during 3 weeks treatment of massively obese children with a very low calorie diet. Eur J Pediatr 1989;149(1):43-7
   PubMedGoogle Scholar
• Alvarez B, Carbo N, Lopez-Soriano J, et al. Effects of interleukin-15 (il-15) on adipose tissue mass in rodent obesity models: evidence for direct il-15 action on adipose tissue. Biochim Biophys Acta 2002;1570(1):33-7
   PubMedGoogle Scholar
• Almendro V, Busquets S, Ametller E, et al. Effects of interleukin-15 on lipid oxidation: disposal of an oral [(14)c]-triolein load. Biochim Biophys Acta 2006;1761(1):37-42
   PubMed Web of Science ®Google Scholar
• Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem J 2006;393(Pt 1):7-20
   PubMedGoogle Scholar